Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Triguero, AnaPedraza, AlexandraPérez-Encinas, ManuelMata-Vázquez, María IsabelVélez, PatriciaFox, LauraGómez-Calafat, MontseGarcía-Delgado, ReginaGasior, MercedesFerrer-Marín, FranciscaGarcía-Gutiérrez, ValentínAngona, AnnaGómez-Casares, María TeresaCuevas, BeatrizMartínez, ClaraPérez, RaúlRaya, José MaríaGuerrero, LucíaMurillo, IldaBellosillo, BeatrizHernández-Boluda, Juan CarlosSanz, CristinaÁlvarez-Larrán, AlbertoOn behalf of the MPN Spanish Group (GEMFIN)2023-05-032023-05-032022-08-30http://hdl.handle.net/10668/19719Hematological control, incidence of complications, and need for cytoreduction were studied in 453 patients with low-risk polycythemia vera (PV) treated with phlebotomies alone. Median hematocrit value decreased from 54% at diagnosis to 45% at 12 months, and adequate hematocrit control over time ( 60 years, and microvascular symptoms constituted the main indications for starting cytoreduction. Median duration without initiating cytoreduction was significantly longer in patients younger than 50 years (enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Low-riskMyelofibrosisPhlebotomiesPolycythemia veraThrombosisHumansLeukemia, Myeloid, AcuteMiddle AgedPhlebotomyPolycythemia VeraPrimary MyelofibrosisRegistriesThrombosisLow-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.research article36042023open access10.1007/s00277-022-04963-z1432-0584PMC9584989https://link.springer.com/content/pdf/10.1007/s00277-022-04963-z.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584989/pdf